ETON vs. SDGR, OCUL, VERA, BHVN, EVO, ETNB, JANX, ANIP, EWTX, and MESO
Should you be buying Eton Pharmaceuticals stock or one of its competitors? The main competitors of Eton Pharmaceuticals include Schrodinger (SDGR), Ocular Therapeutix (OCUL), Vera Therapeutics (VERA), Biohaven (BHVN), Evotec (EVO), 89BIO (ETNB), Janux Therapeutics (JANX), ANI Pharmaceuticals (ANIP), Edgewise Therapeutics (EWTX), and Mesoblast (MESO). These companies are all part of the "pharmaceutical products" industry.
Eton Pharmaceuticals vs. Its Competitors
Eton Pharmaceuticals (NASDAQ:ETON) and Schrodinger (NASDAQ:SDGR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.
Eton Pharmaceuticals has higher earnings, but lower revenue than Schrodinger. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Schrodinger, indicating that it is currently the more affordable of the two stocks.
Eton Pharmaceuticals has a net margin of -9.49% compared to Schrodinger's net margin of -83.39%. Eton Pharmaceuticals' return on equity of -3.15% beat Schrodinger's return on equity.
Eton Pharmaceuticals has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Comparatively, Schrodinger has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500.
In the previous week, Schrodinger had 2 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 7 mentions for Schrodinger and 5 mentions for Eton Pharmaceuticals. Eton Pharmaceuticals' average media sentiment score of 0.52 beat Schrodinger's score of 0.31 indicating that Eton Pharmaceuticals is being referred to more favorably in the media.
27.9% of Eton Pharmaceuticals shares are held by institutional investors. Comparatively, 79.1% of Schrodinger shares are held by institutional investors. 14.9% of Eton Pharmaceuticals shares are held by insiders. Comparatively, 8.6% of Schrodinger shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Eton Pharmaceuticals presently has a consensus price target of $29.67, indicating a potential upside of 113.58%. Schrodinger has a consensus price target of $32.75, indicating a potential upside of 54.12%. Given Eton Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Eton Pharmaceuticals is more favorable than Schrodinger.
Summary
Eton Pharmaceuticals beats Schrodinger on 10 of the 15 factors compared between the two stocks.
Get Eton Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ETON and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ETON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eton Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ETON) was last updated on 7/16/2025 by MarketBeat.com Staff
